BACKGROUND: No randomized controlled trial of prostate cancer screening has been reported and none is likely to be completed in the near future. In the absence of direct evidence, the decision to screen must therefore be based on estimates of benefits and risks. The main risk of screening is overdetection--the detection of cancer that, if left untreated, would not cause death. In this study the authors estimate the level of overdetection that might result from annual screening of men aged 50-70. METHODS: The annual rate of lethal screen-detectable cancer (detectable cancer that would prove fatal before age 85 if left untreated) was calculated from the observed prostate cancer mortality rate in Quebec; the annual rate of all cases of screen-detectable prostate cancer was calculated from 2 recent screening studies. RESULTS: The annual rate of lethal screen-detectable prostate cancer was estimated to be 1.3 per 1000 men. The annual rate of all cases of screen-detectable prostate cancer was estimated to be 8.0 per 1000 men. The estimated case-fatality rate among men up to 85 years of age was 16% (1.3/8.0) (sensitivity analysis 13% to 22%). INTERPRETATION: Of every 100 men with screen-detected prostate cancer, only 16 on average (13 to 22) could have their lives extended by surgery, since the prostate cancer would not cause death before age 85 in the remaining 84 (78 to 87).
BACKGROUND: No randomized controlled trial of prostate cancer screening has been reported and none is likely to be completed in the near future. In the absence of direct evidence, the decision to screen must therefore be based on estimates of benefits and risks. The main risk of screening is overdetection--the detection of cancer that, if left untreated, would not cause death. In this study the authors estimate the level of overdetection that might result from annual screening of men aged 50-70. METHODS: The annual rate of lethal screen-detectable cancer (detectable cancer that would prove fatal before age 85 if left untreated) was calculated from the observed prostate cancer mortality rate in Quebec; the annual rate of all cases of screen-detectable prostate cancer was calculated from 2 recent screening studies. RESULTS: The annual rate of lethal screen-detectable prostate cancer was estimated to be 1.3 per 1000 men. The annual rate of all cases of screen-detectable prostate cancer was estimated to be 8.0 per 1000 men. The estimated case-fatality rate among men up to 85 years of age was 16% (1.3/8.0) (sensitivity analysis 13% to 22%). INTERPRETATION: Of every 100 men with screen-detected prostate cancer, only 16 on average (13 to 22) could have their lives extended by surgery, since the prostate cancer would not cause death before age 85 in the remaining 84 (78 to 87).
Authors: W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole Journal: N Engl J Med Date: 1991-04-25 Impact factor: 91.245
Authors: G W Chodak; R A Thisted; G S Gerber; J E Johansson; J Adolfsson; G W Jones; G D Chisholm; B Moskovitz; P M Livne; J Warner Journal: N Engl J Med Date: 1994-01-27 Impact factor: 91.245
Authors: H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh Journal: JAMA Date: 1992 Apr 22-29 Impact factor: 56.272
Authors: William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick Journal: J Urol Date: 1994-05 Impact factor: 7.450
Authors: Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni Journal: Eur Urol Date: 2014-01-09 Impact factor: 20.096
Authors: Rodolfo Montironi; Elizabeth H Hammond; Daniel W Lin; John L Gore; John R Srigley; Hema Samaratunga; Lars Egevad; Mark A Rubin; John Nacey; Laurence Klotz; Howard Sandler; Anthony L Zietman; Stuart Holden; Peter A Humphrey; Andrew J Evans; Brett Delahunt; Jesse K McKenney; Daniel Berney; Thomas M Wheeler; Arul Chinnaiyan; Lawrence True; Beatrice Knudsen; Jonathan I Epstein; Mahul B Amin Journal: Virchows Arch Date: 2014-10-16 Impact factor: 4.064
Authors: Michael Nasterlack; Gerhard Hoffmann; Peter Messerer; Marvin Gerald Ott; Dirk Pallapies; Marcus Wrede; Andreas Zober Journal: Int Arch Occup Environ Health Date: 2006-07-13 Impact factor: 3.015
Authors: Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong Journal: Hum Mol Genet Date: 2008-01-17 Impact factor: 6.150
Authors: Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning Journal: J Natl Cancer Inst Date: 2009-03-10 Impact factor: 13.506